Home/Pipeline/CB-280

CB-280

Cystic Fibrosis

Preclinical/Phase 1Discontinued

Key Facts

Indication

Cystic Fibrosis

Phase

Preclinical/Phase 1

Status

Discontinued

Company

Calithera Biosciences

About Calithera Biosciences

Calithera Biosciences was founded in 2010 with a mission to develop novel small-molecule drugs targeting critical metabolic pathways in cancer cells and the tumor microenvironment. Its strategy centered on two core platforms: arginase inhibition to modulate immune function and glutaminase inhibition to starve tumors. The company advanced multiple candidates into clinical trials and built a pipeline of ~30 programs, but ultimately discontinued development and wound down operations in 2023 after a strategic review of its clinical prospects.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
ColiFin®	Spexis	Marketed (EU)	Active
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active
KIT2014	Kither Biotech	Phase 2	Active